The validation of a multiple myeloma minimal residual disease flow cytometry assay for use in multi-centric clinical trials

EHA Congress 2026 -- Flow cytometry is a high-throughput and sensitive technique suitable for the detection of very rare cell populations amidst complex mixtures. Consequently, it has become a platform of choice for the detection of minimal residual disease (MRD) in various types of leukemia. For multiple myeloma (MM) patients, the detection of MRD helps determine if any cancerous cells escape treatment. This can constitute an important prognostic measure and help predict the likelihood of disease relapse and/or progression. Therefore, there is considerable interest around the use of MRD as a potential surrogate endpoint in clinical trials.